Join us Friday, December 8th from 8-11pm for Myriad Genetic Laboratories’
LOCATION: Landry’s Seafood House – 3rd floor
517 N. Presa St.
San Antonio, TX 78205
Food and drinks will be served!
We are excited to highlight below studies related to myRisk Hereditary Cancer and EndoPredict:
Poster Discussion PD1-08 // Wednesday, December 6th from 5:00pm-7:00pm
Development and Validation of a Combined Residual Risk Score to Predict Breast Cancer Risk in Unaffected Women Negative for Mutations on a Multi-Gene Hereditary Cancer Panel
Presented by: Elisha Hughes, PhD, Myriad Genetic Laboratories
Poster Discussion P3-08-01 // Thursday, December 7th from 5:00pm-7:00pm
Prognostic performance of EndoPredict in invasive lobular carcinoma
Presented by: Ivana Sestak, Ms, PhD, Queen Mary, University of London | QMUL · Wolfson Institute of Preventive Medicine
General Session 6 GS6-04 // Friday, December 8th at 4:00pm
The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrine therapy in HR+/HER2- breast cancer patients from ABCSG 34.
Presented by: Peter Dubsky, MD, Medical University of Vienna and Breast Center Klinik St. Anna, Lucerne
Myriad is a proud supporter of the following Research to Practice CME event:
Tuesday, December 5, 2017, 8:00 PM – 9:45 PM
at the San Antonio Marriott Rivercenter
Data + Perspectives: Clinical Investigators Explore the Emerging Role of PARP Inhibition in the Management of Breast Cancer
Learn more and register online at: